- Longer-term data from the Phase 3 DISCOVER study evaluating Gilead Sciences' (NASDAQ:GILD -5.2%) Descovy (emtricitabine 200 mg and tenofovir alafenamide 25 mg tablets, F/TAF) for preexposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 infection in at-risk adult men and transgender women showed a favorable safety profile and non-inferior efficacy compared to Truvada (emtricitabine 200 mg and tenofovir disoproxil fumarate 300 mg, F/TDF). The results were presented at the Conference on Retroviruses and Opportunistic Infections in Boston.
- At week 96, participants receiving Descovy continued to show beneficial changes in key biomarkers of renal and bone safety.
- Descovy's non-inferiority to Truvada was demonstrated in the overall study population as well as subpopulations of participants older than 50 and younger than 25. A separate analysis showed that both drugs were effective and well-tolerated in Black and Hispanic/Latinx subjects.
- The FDA approved Descovy in October 2019 for HIV PrEP.